Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
The current study aimed to explore the clinical utility of CNV-seq in prenatal diagnosis by comparing the pathogenic detection rates of copy number variants (CNVs) in pregnant women who underwent amniocentesis for various indications and across different CNV fragment sizes. A total of 1,118 pregnant women who received CNV-seq testing were included in the cohort and categorized into eight groups (Groups A to H) based on their testing indications, with the mixed group (Group H) serving as the reference. The top three groups with the highest pathogenic detection rates were high-risk NIPT (Group A), parental chromosomal abnormalities (Group D), and high-risk trisomy 18 (Group F), with detection rates of 92.16% (141/153), 80% (4/5), and 70% (14/20), respectively. The pathogenic CNV detection rate in our reference group (Group H) was 69.02% (127/184). A binary logistic regression analysis comparing the other seven groups against Group H showed that the detection rate in Group A was significantly higher than that in Group H (P < 0.05), while Groups B, C, E, and G had significantly lower detection rates. Furthermore, based on CNV fragment size, cutoffs were established at 1 Mb and 5 Mb, and the study cohort was further divided into four groups (Groups I to IV). Using the group with multiple CNVs (Group IV) as the reference, the pathogenic detection rates for each group were calculated. Binary logistic regression analysis revealed that Group I had a significantly lower detection rate than Group IV (P < 0.05), while Group III exhibited a significantly higher detection rate (P < 0.05). These findings suggest that abnormal NIPT results are often associated with a higher pathogenic detection rate, and larger CNV fragments exceeding 5 Mb are more likely to be pathogenic. This study provides crucial insights into the clinical application of CNV-seq in prenatal diagnosis, emphasizing the importance of abnormal NIPT results and CNV fragment size in clinical interpretation, thereby facilitating more accurate prenatal risk assessment.
The current study aimed to explore the clinical utility of CNV-seq in prenatal diagnosis by comparing the pathogenic detection rates of copy number variants (CNVs) in pregnant women who underwent amniocentesis for various indications and across different CNV fragment sizes. A total of 1,118 pregnant women who received CNV-seq testing were included in the cohort and categorized into eight groups (Groups A to H) based on their testing indications, with the mixed group (Group H) serving as the reference. The top three groups with the highest pathogenic detection rates were high-risk NIPT (Group A), parental chromosomal abnormalities (Group D), and high-risk trisomy 18 (Group F), with detection rates of 92.16% (141/153), 80% (4/5), and 70% (14/20), respectively. The pathogenic CNV detection rate in our reference group (Group H) was 69.02% (127/184). A binary logistic regression analysis comparing the other seven groups against Group H showed that the detection rate in Group A was significantly higher than that in Group H (P < 0.05), while Groups B, C, E, and G had significantly lower detection rates. Furthermore, based on CNV fragment size, cutoffs were established at 1 Mb and 5 Mb, and the study cohort was further divided into four groups (Groups I to IV). Using the group with multiple CNVs (Group IV) as the reference, the pathogenic detection rates for each group were calculated. Binary logistic regression analysis revealed that Group I had a significantly lower detection rate than Group IV (P < 0.05), while Group III exhibited a significantly higher detection rate (P < 0.05). These findings suggest that abnormal NIPT results are often associated with a higher pathogenic detection rate, and larger CNV fragments exceeding 5 Mb are more likely to be pathogenic. This study provides crucial insights into the clinical application of CNV-seq in prenatal diagnosis, emphasizing the importance of abnormal NIPT results and CNV fragment size in clinical interpretation, thereby facilitating more accurate prenatal risk assessment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.